{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:36:14Z","timestamp":1786995374257,"version":"build-2736575974"},"reference-count":29,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T00:00:00Z","timestamp":1737072000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100017686","name":"Fujian Provincial Health Technology Project","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100017686","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Methods &amp; Clinical Development"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.omtm.2025.101413","type":"journal-article","created":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T13:31:39Z","timestamp":1737466299000},"page":"101413","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Intravenous esketamine in pediatric Rett syndrome: An open-label, early phase 1 pilot study"],"prefix":"10.1016","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4554-2247","authenticated-orcid":false,"given":"Huiping","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caimei","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuchao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuping","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yajun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiubin","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiu","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtm.2025.101413_bib1","article-title":"Rett Syndrome: A Tale of Altered Genetics, Synaptic Plasticity, and Neurodevelopmental Dynamics","volume":"15","author":"Oluigbo","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.omtm.2025.101413_bib2","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/s41583-018-0006-3","article-title":"Rett syndrome: insights into genetic, molecular and circuit mechanisms","volume":"19","author":"Ip","year":"2018","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.omtm.2025.101413_bib3","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1126\/science.1153252","article-title":"MeCP2, a key contributor to neurological disease, activates and represses transcription","volume":"320","author":"Chahrour","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.omtm.2025.101413_bib4","doi-asserted-by":"crossref","first-page":"3880","DOI":"10.1038\/s41467-024-47395-1","article-title":"MeCP2 binds to methylated DNA independently of phase separation and heterochromatin organisation","volume":"15","author":"Pantier","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtm.2025.101413_bib5","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S1474-4422(20)30217-9","article-title":"Advances in understanding of Rett syndrome and MECP2 duplication syndrome: prospects for future therapies","volume":"19","author":"Sandweiss","year":"2020","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.omtm.2025.101413_bib6","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1038\/s41591-023-02398-1","article-title":"Trofinetide for the treatment of Rett syndrome: a randomized phase 3 study","volume":"29","author":"Neul","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtm.2025.101413_bib7","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1093\/brain\/awab182","article-title":"Engineered microRNA-based regulatory element permits safe high-dose miniMECP2 gene therapy in Rett mice","volume":"144","author":"Sinnett","year":"2021","journal-title":"Brain"},{"key":"10.1016\/j.omtm.2025.101413_bib8","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2023.1172805","article-title":"Advanced genetic therapies for the treatment of Rett syndrome: state of the art and future perspectives","volume":"17","author":"Palmieri","year":"2023","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.omtm.2025.101413_bib9","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41386-023-01632-1","article-title":"Ketamine in neuropsychiatric disorders: an update","volume":"49","author":"Johnston","year":"2024","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.omtm.2025.101413_bib10","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.biopsych.2015.05.018","article-title":"Cell-Specific Regulation of N-Methyl-D-Aspartate Receptor Maturation by Mecp2 in Cortical Circuits","volume":"79","author":"Mierau","year":"2016","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.omtm.2025.101413_bib11","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.biopsych.2016.03.1045","article-title":"N-Methyl-D-Aspartate Receptors, Ketamine, and Rett Syndrome: Something Special on the Road to Treatments?","volume":"79","author":"Katz","year":"2016","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.omtm.2025.101413_bib12","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1002\/1531-8249(199904)45:4<541::AID-ANA21>3.0.CO;2-2","article-title":"Development of amino acid receptors in frontal cortex from girls with Rett syndrome","volume":"45","author":"Blue","year":"1999","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.omtm.2025.101413_bib13","doi-asserted-by":"crossref","first-page":"13860","DOI":"10.1523\/JNEUROSCI.2159-12.2012","article-title":"Brain activity mapping in Mecp2 mutant mice reveals functional deficits in forebrain circuits, including key nodes in the default mode network, that are reversed with ketamine treatment","volume":"32","author":"Kron","year":"2012","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.omtm.2025.101413_bib14","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.biopsych.2015.08.018","article-title":"Chronic Administration of the N-Methyl-D-Aspartate Receptor Antagonist Ketamine Improves Rett Syndrome Phenotype","volume":"79","author":"Patrizi","year":"2016","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.omtm.2025.101413_bib15","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.neuron.2019.03.013","article-title":"Altered Connectivity in Depression: GABA and Glutamate Neurotransmitter Deficits and Reversal by Novel Treatments","volume":"102","author":"Duman","year":"2019","journal-title":"Neuron"},{"key":"10.1016\/j.omtm.2025.101413_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.ynstr.2020.100239","article-title":"The stress susceptibility factor FKBP51 controls S-ketamine-evoked release of mBDNF in the prefrontal cortex of mice","volume":"13","author":"Anderzhanova","year":"2020","journal-title":"Neurobiol. Stress"},{"key":"10.1016\/j.omtm.2025.101413_bib17","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/nature10130","article-title":"NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses","volume":"475","author":"Autry","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.omtm.2025.101413_bib18","doi-asserted-by":"crossref","first-page":"214","DOI":"10.4161\/epi.2.4.5212","article-title":"MeCP2 deficiency in the brain decreases BDNF levels by REST\/CoREST-mediated repression and increases TRKB production","volume":"2","author":"Abuhatzira","year":"2007","journal-title":"Epigenetics"},{"key":"10.1016\/j.omtm.2025.101413_bib19","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.19374","article-title":"Loss of MeCP2 disrupts cell autonomous and autocrine BDNF signaling in mouse glutamatergic neurons","volume":"5","author":"Sampathkumar","year":"2016","journal-title":"Elife"},{"key":"10.1016\/j.omtm.2025.101413_bib20","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/s41380-021-01121-1","article-title":"Molecular mechanisms underlying the antidepressant actions of arketamine: beyond the NMDA receptor","volume":"27","author":"Wei","year":"2022","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.omtm.2025.101413_bib21","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s00228-015-1826-y","article-title":"Population pharmacokinetics of S-ketamine and norketamine in healthy volunteers after intravenous and oral dosing","volume":"71","author":"Fanta","year":"2015","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.omtm.2025.101413_bib22","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1007\/s00213-023-06480-x","article-title":"Oral ketamine may offer a solution to the ketamine conundrum","volume":"240","author":"Dutton","year":"2023","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.omtm.2025.101413_bib23","doi-asserted-by":"crossref","first-page":"4764","DOI":"10.1523\/JNEUROSCI.17-12-04764.1997","article-title":"Glutamatergic enteric neurons","volume":"17","author":"Liu","year":"1997","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.omtm.2025.101413_bib24","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.biopsych.2015.10.018","article-title":"Intravenous Esketamine in Adult Treatment-Resistant Depression: A Double-Blind, Double-Randomization, Placebo-Controlled Study","volume":"80","author":"Singh","year":"2016","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.omtm.2025.101413_bib25","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1177\/0883073815579707","article-title":"Improving Treatment Trial Outcomes for Rett Syndrome: The Development of Rett-specific Anchors for the Clinical Global Impression Scale","volume":"30","author":"Neul","year":"2015","journal-title":"J.\u00a0Child Neurol."},{"key":"10.1016\/j.omtm.2025.101413_bib26","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1212\/WNL.56.11.1486","article-title":"MeCP2 mutations in children with and without the phenotype of Rett syndrome","volume":"56","author":"Hoffbuhr","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.omtm.2025.101413_bib27","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1111\/1469-7610.00236","article-title":"The Rett Syndrome Behaviour Questionnaire (RSBQ): refining the behavioural phenotype of Rett syndrome","volume":"43","author":"Mount","year":"2002","journal-title":"J.\u00a0Child Psychol. Psychiatry"},{"key":"10.1016\/j.omtm.2025.101413_bib28","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1352\/1944-7558-125.6.493","article-title":"A Psychometric Evaluation of the Motor-Behavioral Assessment Scale for Use as an Outcome Measure in Rett Syndrome Clinical Trials","volume":"125","author":"Raspa","year":"2020","journal-title":"Am. J. Intellect. Dev. Disabil."},{"key":"10.1016\/j.omtm.2025.101413_bib29","first-page":"176","article-title":"Development and psychometric properties of the Chinese version of Children\u2032s Sleep Habits Questionnaire","volume":"45","author":"Li","year":"2007","journal-title":"Chin. J. Pediatrics"}],"container-title":["Molecular Therapy Methods &amp; Clinical Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050125000087?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050125000087?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T20:57:24Z","timestamp":1742504244000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2329050125000087"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S2329050125000087"],"URL":"https:\/\/doi.org\/10.1016\/j.omtm.2025.101413","relation":{},"ISSN":["2329-0501"],"issn-type":[{"value":"2329-0501","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intravenous esketamine in pediatric Rett syndrome: An open-label, early phase 1 pilot study","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Methods & Clinical Development","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtm.2025.101413","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"101413"}}